Re-watch this meeting below:
Tuesday 11 August, 14:00 – 15:00 BST
Organised by Pete Aldiss, University of Edinburgh, UK and Jo Lewis, University of Cambridge, UK
Hormones released from the gut (e.g. GLP-1) are central to the control of appetite and insulin release and are the basis for drugs in the treatment of T2DM and obesity. Drugs targeting enteroendocrine L-cells are under development but are limited by current experimental models.
Emily Miedzybrodzka (University of Cambridge, UK) described the labelling and characterisation of human GLP-1 secreting L-cells in primary organoid culture. This opens new avenues to explore L-cell function and developing drugs which target the enteroendocrine system. In the second talk, Katrina Viloria (University of Birmingham, UK) described pancreatic islet function and glucagon secretion through vitamin D binding protein and how the stage is now set for investigating disease risk in individuals with type 2 diabetes.
This is part of the ‘Physiology of Obesity: From Mechanisms to Medicine’ series.
Hear from Early Career Researchers as they explore the molecular, cellular, and neural mechanisms, as well as behavioural aspects, underlying obesity.